Investors bought shares of Eli Lilly and Company (NYSE:LLY) on weakness during trading on Monday. $90.08 million flowed into the stock on the tick-up and $51.41 million flowed out of the stock on the tick-down, for a money net flow of $38.67 million into the stock. Of all equities tracked, Eli Lilly and had the 14th highest net in-flow for the day. Eli Lilly and traded down ($0.60) for the day and closed at $85.95
LLY has been the subject of a number of recent analyst reports. Jefferies Group LLC reaffirmed a “buy” rating and issued a $89.00 price target on shares of Eli Lilly and in a research note on Monday, September 11th. BMO Capital Markets reaffirmed an “underperform” rating and issued a $71.00 price target (down from $73.00) on shares of Eli Lilly and in a research note on Wednesday, September 6th. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $105.00 price target (up from $103.00) on shares of Eli Lilly and in a research note on Friday, September 8th. Zacks Investment Research raised Eli Lilly and from a “hold” rating to a “buy” rating and set a $94.00 price target for the company in a research note on Monday, July 17th. Finally, Morgan Stanley reaffirmed a “hold” rating and issued a $86.00 price target on shares of Eli Lilly and in a research note on Friday, September 15th. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have issued a buy rating to the company’s stock. Eli Lilly and currently has an average rating of “Hold” and a consensus price target of $88.97.
The stock has a market capitalization of $94.63 billion, a PE ratio of 37.05 and a beta of 0.34. The firm has a 50-day moving average price of $83.56 and a 200-day moving average price of $82.19.
Eli Lilly and (NYSE:LLY) last released its quarterly earnings data on Tuesday, July 25th. The company reported $1.11 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.05 by $0.06. The firm had revenue of $5.82 billion during the quarter, compared to the consensus estimate of $5.60 billion. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The company’s quarterly revenue was up 7.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.86 earnings per share. On average, analysts expect that Eli Lilly and Company will post $4.16 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 8th. Stockholders of record on Wednesday, November 15th will be issued a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a dividend yield of 2.42%. Eli Lilly and’s dividend payout ratio is 90.04%.
In other news, major shareholder Lilly Endowment Inc sold 220,000 shares of the business’s stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $83.09, for a total transaction of $18,279,800.00. Following the completion of the sale, the insider now owns 124,049,283 shares in the company, valued at $10,307,254,924.47. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In the last 90 days, insiders have sold 990,000 shares of company stock valued at $82,949,650. Corporate insiders own 0.20% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Acrospire Investment Management LLC grew its holdings in Eli Lilly and by 16.7% during the second quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock worth $115,000 after buying an additional 200 shares in the last quarter. MPS Loria Financial Planners LLC bought a new stake in Eli Lilly and during the second quarter worth $128,000. San Francisco Sentry Investment Group CA bought a new stake in Eli Lilly and during the second quarter worth $129,000. Heritage Trust Co bought a new stake in Eli Lilly and during the first quarter worth $135,000. Finally, Point72 Asia Hong Kong Ltd grew its holdings in Eli Lilly and by 237.4% during the first quarter. Point72 Asia Hong Kong Ltd now owns 1,761 shares of the company’s stock worth $148,000 after buying an additional 1,239 shares in the last quarter. Hedge funds and other institutional investors own 75.53% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This story was first published by Markets Daily and is owned by of Markets Daily. If you are reading this story on another website, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this story can be read at https://www.themarketsdaily.com/2017/10/17/traders-buy-shares-of-eli-lilly-and-company-lly-on-weakness-2.html.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.